Sionna Therapeutics Announce $182M Series C Financing

Waltham, MA, March 8, 2024 (Cystic Fibrosis News Today) -- Sionna Therapeutics has secured $182 million in financing to propel the advancement of small molecules engineered to address cystic fibrosis (CF) by targeting a critical segment of the CFTR protein known as the first nucleotide-binding domain (NBD1). Founded in 2019 and incubated by investment firm RA Capital, the company aims to challenge Vertex Pharmaceuticals’ market-leading cystic fibrosis business. The company has 5 drugs in development, all of which work differently than Vertex’s medicines. Two are in clinical testing, and two more could join them by the end of 2024.

Read full article here.